Critères clinico-radiologiques d’introduction d’un traitement de seconde ligne dans la sclérose en plaques : l’expérience de 294 patients traités par interféron suivis pendant 5 ans
暂无分享,去创建一个
G. Defer | C. Lebrun-Frénay | M. Clanet | B. Fontaine | G. Edan | S. Vukusic | T. Moreau | D. Brassat | M. Debouverie | H. Merle | E. Lepage | Pierre Gouraud | É. Schmit | S. Mrejem | N. Couturier | L. Parmentier
[1] S. Sorbi,et al. Response to interferon-beta therapy in relapsing-remitting multiple sclerosis: a comparison of different clinical criteria , 2006, Multiple sclerosis.
[2] V. Tomassini,et al. Predictors of long–term clinical response to interferon beta therapy in relapsing multiple sclerosis , 2006, Journal of Neurology.
[3] X. Montalban,et al. Defining the response to interferon‐β in relapsing‐remitting multiple sclerosis patients , 2006, Annals of neurology.
[4] R. Rudick,et al. Defining interferon β response status in multiple sclerosis patients , 2004 .
[5] M. Clanet,et al. Treatment response in relation to inflammatory and axonal surrogate marker in multiple sclerosis , 2004, Multiple sclerosis.
[6] X. Montalban,et al. Clinical characteristics of responders to interferon therapy for relapsing MS , 2004, Neurology.